These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23170992)

  • 1. Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.
    Farkouh RA; Klok RM; Postma MJ; Roberts CS; Strutton DR
    Expert Rev Vaccines; 2012 Oct; 11(10):1235-47. PubMed ID: 23170992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
    Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
    J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
    Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR
    Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential cost-effectiveness of infant pneumococcal vaccines in Australia.
    Newall AT; Creighton P; Philp DJ; Wood JG; MacIntyre CR
    Vaccine; 2011 Oct; 29(45):8077-85. PubMed ID: 21864617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.
    Blank PR; Szucs TD
    Vaccine; 2012 Jun; 30(28):4267-75. PubMed ID: 22521287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Giglio N; Gentile A; Jimenez SG; Jáuregui B; Clark AD; Diosque M; Vizzotti C
    Vaccine; 2011 Jul; 29(31):4963-72. PubMed ID: 21621575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.
    Stoecker C; Hampton LM; Link-Gelles R; Messonnier ML; Zhou F; Moore MR
    Pediatrics; 2013 Aug; 132(2):e324-32. PubMed ID: 23821695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey.
    Türel O; Kisa A; McIntosh ED; Bakir M
    Value Health; 2013; 16(5):755-9. PubMed ID: 23947968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
    Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
    Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine.
    Wasserman M; Sings HL; Jones D; Pugh S; Moffatt M; Farkouh R
    Expert Rev Vaccines; 2018 Jan; 17(1):71-78. PubMed ID: 29164952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.